Special Issue

New Therapies and Therapeutic Approaches in Multiple Myeloma

Message from the Guest Editors

Multiple myeloma (MM) is a hematological malignancy characterized by high tendency to relapse and to develop drug resistance. In recent years, the development and the use of monoclonal antibodies against different cell surface antigens overexpressed by MM cells such as CD38, SLAMF7, and BCMA has helped to change the therapeutic paradigm of MM. New possible therapeutic targets for immunotherapy or the use of CART cell technology are under clinical investigation, with very promising results. Moreover, selective drug inhibitors such as those anti-BCL-2 and MCL-1 apoptotic proteins or against the nuclear transport exportin (selinexor) are under experimental and clinical investigation. Combination treatment using both the main class of drugs as proteasome inhibitors and immunomodulatory drugs and monoclonal antibodies seems to extremely prolong the duration of the response of MM patients.

This Special Issue will address the most recent and relevant scientific findings regarding advances in the treatment of MM.

Guest Editors

Prof. Dr. Nicola Giuliani

Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy

Dr. Francesca Gay

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, Italy

Dr. Sara Bringhen

Division of Haematology, University of Turin, Turin, Italy

Deadline for manuscript submissions

closed (31 July 2020)



Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9 CiteScore 5.2 Indexed in PubMed



mdpi.com/si/30270

Journal of Clinical Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine*'s (*JCM*) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).